

Holders of warrants in Simris Group AB (publ) have declared their intention to exercise 220 million warrants amounting to total proceeds of MEUR 1

Simris Group AB (publ) ("Simris Group" or the "Company") has today received information from certain holders of warrants of series 2025/2027 and series 2026/2027 in Simris Group that they intend to exercise 220 million warrants at the subscription price of SEK 0.05 per class B share, amounting to total proceeds of MEUR 1 before transaction costs.

On 16 December 2025, the board of directors of Simris Group resolved on a directed issue of units consisting of shares and warrants of series 2025/2027 by virtue of authorisation from the annual general meeting of 2025. Furthermore, on 19 January 2026, an extraordinary general meeting resolved on a directed issue of units consisting of shares and warrants of series 2026/2027 to certain investors. For more information regarding the warrants and the issues, please see the press release disclosed by the Company on 16 December 2025.

Simris Group has today received information from certain holders of warrants of series 2025/2027 and 2026/2027 that they intend to exercise 220 million warrants, whereof 185,200,000 warrants of series 2025/2027 and 34,800,000 warrants of series 2026/2027. The subscription price is SEK 0.05 per new class B share entailing that Simris Group will receive proceeds amounting to MEUR 1 before transaction costs. Following the exercise, a total of 721,810,534 warrants will remain outstanding, of which 474,800,000 are of series 2025/2027 and 247,010,534 are of series 2026/2027.

Through the exercise of the warrants, a total of 220,000,000 new class B shares will be issued by the Company, increasing the total number of shares in the Company from 1,349,793,273 to 1,569,793,273, corresponding to a dilution of approximately 14.01 per cent. The share capital will increase by SEK 2,200,000 from SEK 13,497,932.73 to SEK 15,697,932.73.

Contact Details:

Daniel Kubitzka
Interim CEO of Simris Group AB
Email: daniel.kubitzka@simris.com
Mobile: +33 6 71 04 21 52
www.simrisgroup.com

About Simris Group AB (PUBL):

Simris Group is a biologics company identifying and commercialising high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in biopharmaceuticals, dietary supplements and cosmetics.

Simris Group's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.

Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: info@amudova.se.

This information is information that Simris Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-07-06 17:31 CEST.

Attachments

[Holders of warrants in Simris Group AB \(publ\) have declared their intention to exercise 220 million warrants amounting to total proceeds of MEUR 1](#)